Ivosidenib and Enasidenib, which are well-tested, FDA-approved drugs for relapsed/refractory IDH-mutated AML, show great potential for MDS targeting by eliminating oncometabolite 2-HG [87] (Figure 1). This evidence concerns the gene IDH1 and acute myeloid leukemia.